SCM
Stonepine Capital Management Portfolio holdings
AUM
$126M
1-Year Est. Return
70.12%
This Fund
S&P 500
1 Year Est. Return
+70.12%
AUM
$126M
AUM Growth
+$3.43M
(+2.8%)
Holding
86
Top Buys
| 1 | +$272M | |
| 2 | +$4.81M | |
| 3 | +$3.92M | |
| 4 |
Inhibikase Therapeutics
IKT
|
+$2.57M |
| 5 |
Adicet Bio
ACET
|
+$2.43M |
Top Sells
| 1 | +$3.74M | |
| 2 | +$2.6M | |
| 3 | +$2.51M | |
| 4 |
Zevra Therapeutics
ZVRA
|
+$2.28M |
| 5 |
Surrozen
SRZN
|
+$2.21M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| 3 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
CytomX Therapeutics
CTMX
$910M
| – | – |
-125,000
|
|
||
|
DVAX
77
DELISTED
Dynavax Technologies
DVAX
| – | – |
-108,094
|
|
||
78
Establishment Labs
ESTA
$2.29B
| – | – |
-10,585
|
|
||
79
Health Catalyst
HCAT
$115M
| – | – |
-155,551
|
|
||
80
Solana Company
HSDT
$98.7M
| – | – |
-20,000
|
|
||
81
Jasper Therapeutics
JSPR
$38.6M
| – | – |
-20,200
|
|
||
82
Larimar Therapeutics
LRMR
$441M
| – | – |
-25,000
|
|
||
83
Ultragenyx Pharmaceutical
RARE
$2.26B
| – | – |
-20,000
|
|
||
|
ALMS
84
Alumis Inc
ALMS
$3.7B
| – | – |
-300,000
|
|
||
|
GRCE
85
Grace Therapeutics
GRCE
$66.4M
| – | – |
-211,010
|
|
||
|
WHWK
86
Whitehawk Therapeutics
WHWK
$165M
| – | – |
-35,253
|
|